News & Updates
Filter by Specialty:
Bimekizumab shows promise across the spectrum of axial spondyloarthritis
Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.
Bimekizumab shows promise across the spectrum of axial spondyloarthritis
18 Jun 2022
RELIEVE-AD: Atopic dermatitis patients see rapid, sustained improvements with dupilumab
The biologic dupilumab appears to be a hit with atopic dermatitis (AD) patients treated in the real-world setting, with patients experiencing prompt improvements in multiple aspects of disease control that persisted through 1 year, as shown in the results of the RELIEVE-AD* study.
RELIEVE-AD: Atopic dermatitis patients see rapid, sustained improvements with dupilumab
17 Jun 2022
Tradition, conditioning influence parental perceptions of GERD in Asian infants
In the first 3 months of a newborn’s life, the prevalence of gastroesophageal reflux disease (GERD) is at its peak, but most infants outgrow it by age 1 year, according to a Singapore study, noting that those breastfed at 3 weeks have a lower likelihood of GERD.
Tradition, conditioning influence parental perceptions of GERD in Asian infants
17 Jun 2022
Antihistamines potentially beneficial for knee OA
The use of antihistamines was associated with reduced structural progression in knee osteoarthritis (OA), according to a post hoc analysis of two large phase III trials.
Antihistamines potentially beneficial for knee OA
17 Jun 2022
Belt-type device slows breathing rate to ease test anxiety in students
Device-guided breathing (DGB), as facilitated by the RESPeRATE device, appears to reduce test anxiety and can boost subsequent test performance among students, according to a recent study.
Belt-type device slows breathing rate to ease test anxiety in students
17 Jun 2022
Antimicrobial peptide levels may gauge COVID-19 progression risk
The levels of serum levels of LL-37, an antimicrobial peptide whose expression is stimulated by vitamin D, may help assess the risk of disease progression in COVID-19 patients, reports a recent study.
